Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 12, 2007

GSK Settles Infringement Case with Watson for $35M

  • Watson Pharmaceuticals says that it reached a settlement with GlaxoSmithKline (GSK) on a patent litigation related to GSK’s antidepressant.

    In December 2005, Andrx, now owned by Watson, filed a lawsuit in the U.S. District Court for the Southern District of Florida against GSK alleging that the 150-mg dose of Wellbutrin XL infringed Andrx' patent.

    Under terms of the settlement, Andrx will receive a one-time payment of $35 million. GSK also received a royalty-bearing license to the relevant patent.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »